

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/00, 31/42, 31/165, 31/415, 31/44, 31/41, 31/19, 31/38, 31/35, 31/045, 31/365, 31/05

A3

(11) International Publication Number:

WO 97/11690

(43) International Publication Date:

3 April 1997 (03.04.97)

(21) International Application Number:

PCT/US96/15435

(22) International Filing Date:

25 September 1996 (25.09.96)

(81) Designated States: AU, CA, CU, DE, IL, JP, MX, NZ, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(30) Priority Data:

60/004,626 08/672,215 29 September 1995 (29.09.95) U

25 June 1996 (25.06.96)

US US

(71) Applicant: MICROCIDE PHARMACEUTICALS, INC. [US/US]; 850 Maude Avenue, Mountain View, CA 94043 (US).

(72) Inventors: BAO, Ying; 1291 Vincente Drive #248, Sunnyvale, CA 94086 (US). BOGGS, Amy; 490 Sherwood Way #3, Menlo Park, CA 94025 (US). CONTAG, Pamela, R.; 6110 Bollinger Road, San Jose, CA 95129 (US). FEDERSPIEL, Nancy, A.; 1345 Altschul Avenue, Menlo Park, CA 94025 (US). HEBERT, Alan; 450 8th Avenue, Menlo Park, CA 94025 (US). HECKER, Scott; 16387 Englewood Avenue, Las Gatos, CA 95032 (US). MALOUIN, Francois; 18400 Overlook Road, #6, Los Gatos, CA 95030 (US).

(74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071 (US). Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report: 12 September 1997 (12.09.97)

(54) Title: INHIBITORS OF REGULATORY PATHWAYS

(57) Abstract

Methods are provided for screening for potential inhibitors of bacterial, or other microbial, global pathogenesis gene regulators and other gene regulators. Methods are also provided for treating microbial (e.g., bacterial) infections using such inhibitors. Also included are pharmaceutical compositions containing such inhibitors. The screening methods involve detecting whether the activity of a global pathogenesis gene regulator is altered in the presence of a test compound.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE			Mexico
AU	Australia	GN	Guinea	NE	Niger
ВВ	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ircland	NZ	New Zealand
BG	Bulgaria	IT	italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Beisrus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhatan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajlkistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	ÜĞ	Uganda
FI	Pinland	ML	Mali	US	United States of America
FR	Prance	MN	Mongoila	UZ	Uzbekistan
GA	Gabon	MR	Massritania	VN	Viet Nam

Inter nat Application No PCT/US 96/15435

				PC	T/US 96/154	35
IPC 6	A61K31/41 A61K A61K31/365 A61K	K31/42 K31/19 K31/05	•	•	A61K31/4 A61K31/0	4 45
	to International Patent Classification OS SEARCHED	(IPC) or to be	oth national classifica	tion and IPC		
Minimum	documentation searched (classification	on system folio	wed by classification	symbols)		
IPC 6	A61K	•		->		
Document	ation searched other than minimum d	ocumentation (o the extent that suci	documents are included i	n the fields searched	
Electronic	data have consulted dumma the union			·		
	data base consulted during the interna	tuonai search (name of data base as	nd, where practical, search	terms used)	
C. DOCUM	MENTS CONSIDERED TO BE RE	LEVANT				·
Category '	Citation of document, with indicati	on, where appr	opriate, of the releva	nt passages	Re	levant to claim No.
		· · · · · · · · · · · · · · · · · · ·				
X	JOURNAL OF BACTE	RIOLOGY,			1	-7,9,
	vol. 176, no. 13, pages 4168-4172,	, July 19	994, 5400		1	1-18,
	CHEUNG A L ET AL:	* "CLON	ING AND SEV	HENCING		0,22,
	UF SARA OF STAPHY	/LOCOCCU:	S AUREUS. A	GENE		0,51, 9-81,
	KEQUIKED FOR THE	EXPRESS	ION OF AGR"			3,85-87
	see the whole doo	:ument				,,,,
X,P	WO 96 10579 A (UN 1996		/ORK) 11 Apr	ril	1.	-22
]	see the whole doc	ument				
Х	WO 94 02586 A (AG ;PARK SIMON FEARO see page 2, line	N (GB))	3 February	RES 1994	1	
			-/			
			•		1	}
						ł
X Furthe	r documents are listed in the continu	ation of box C.	X	Patent family members	are listed in annex.	
	gories of cited documents :		T' la	er document published aft	er the international G	line data
A" documen considen	t defining the general state of the art ed to be of particular relevance	which is not		priority date and not in c		
E" earlier do	current but published on or after the	international		vention cument of particular relev		1
L' document	which may throw doubts on priority	daim(s) or		nnot be considered novel a volve an inventive step wh	OF CURRON be assented	
- California (cited to establish the publication date or other special reason (as specified)		Y do	cument of particular releva	snot the claimed inv	
outer tile			Ų.	nnot be considered to involutional is combined with a section being the combination being the considered to involve the combination being the combination	DDE OF MORE When eur	de demo
document later than	published prior to the internstional (Iling date but	123	die arr		n skilled
ate of the act	rual completion of the international a	rarch		current member of the san te of mailing of the interna		
18	July 1997					
				3 1. 0	/. 9 /	1
une and mai	ling address of the ISA European Patent Office, P.B. 5818 (Patentian ?	Au	horized officer		
	NL - 2280 HV Ripwijk Tel. (+31-70) 340-2040, Tx. 31 651 Fax: (+31-70) 340-3016			Trifilieff-Ri	olo. S	
DCT FO					, -	[

. 1

Inter mail Application No PCT/US 96/15435

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х,Р	LV 10 915 B (BF ESSE SIA) 20 April 1996	1-23, 50-52,
ļ	see page 7; table 1	79-87
X	JOURNAL OF BACTERIOLOGY, vol. 175, no. 24, December 1993, pages 7875-7879, XP000645497 HART M E ET AL: "THE EXTRACELLULAR PROTEIN REGULATOR (XPR) AFFECTS EXOPROTEIN AND AGR MRNA LEVELS IN STAPHYLOCOCCUS AUREUS" see the whole document	1-8, 11-19, 22,50, 51, 79-82, 85-87
K	INFECTION AND IMMUNITY, vol. 60, no. 8, August 1992, pages 3381-3388, XP000645259 REGASSA L B ET AL: "GLUCOSE AND NONMAINTAINED PH DECREASE EXPRESSION OF THE ACCESSORY GENE REGULATOR (AGR) IN STAPHYLOCOCCUS AUREUS" see the whole document	1-7, 11-18, 22,50, 51, 79-81, 85-87
	CANADIAN JOURNAL OF MICROBIOLOGY, vol. 40, August 1994, pages 677-681, XP000645258 GIRAUDO A T ET AL: "CHARACTERIZATION OF A TN551-MUTANT OF STAPHYLOCOCCUS AUREUS DEFECTIVE IN THE PRODUCTION OF SEVERAL EXOPROTEINS" see the whole document	1-3,5,7, 10-14, 16,18, 21,22, 50,51, 79,80, 84,85
	PHYTOCHEMISTRY, vol. 36, no. 4, 1994, XP000645959 ULUBELEN A ET AL: "TERPENOIDS FROM SALVIA SCLAREA" see the whole document	23,24, 52,53
	P.N.A.S, vol. 90, 1993, pages 965-969, XP002035604 ROYCHOUDHURY ET AL: "inhibitors of 2-component signal transduction systems: inhibition of alginate gene activation in Pseudomonas aeruginosa" cited in the application see the whole document	88-90, 98,99
	PATENT ABSTRACTS OF JAPAN vol. 095, no. 007, 31 August 1995 & JP 07 089924 A (SHIRATORI SEIYAKU KK), 4 April 1995, see abstract	61,62
	·	

1

Inte onal Application No PCT/US 96/15435

C.(Continu	ndon) DOCUMENTS CONSIDERED TO BE RELEVANT	PCT/US 96/15435
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 31 08 067 A (BAYER AG) 16 September 1982 see page 19; example 3	61,62
A	MED. PARAZITOL. PARAZIT. BOLEZNI, vol. 6, 1991, pages 52-53, XP002035605 MIKHAILITSYN ET AL: "search for new antiparasitic agents" see page 53; table 2	40,41
	,	
	continuation of second cheet) (July 1992)	

· 1

Intr 'tional application No.

PCT/US 96/15435

Box 1 Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claim(s) 1-49 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. 2. Claims Nos.:	
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:	
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
SEE NEXT PAGE	
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
3. X As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:	1
Subjects 1 5 and 9 Please see next page for further information	
No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Remark on Pretest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	
-	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

subject 1: claims 1 to 22 (all partially), 23, 24, 50-51 (both partially), 52, 53, 79-103 (all 24 partially): use of a compound of formula 1 or 1A to treat or prevent a bacterial infection, compositions comprising said compound, method of screening for such a compound, method of producing an antibacterial agent comprising this compound

subject 2: claims 1 to 22 (all partially), 25, 26, 27, 50-51 (both partially), 54, 55, 56, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 2 or 2A (as far as not comprised in subject 1)

subject 3: claims 1 to 22 (all partially), 28, 29, 50-51 (both partially), 57, 58, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 4 or 4A (as far as not comprised in subjects 1-2)

subject 4: claims 1 to 22 (all partially), 30, 31, 50-51 (both partially), 59, 60, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 5 or 5A (as far as not comprised in subjects 1-3)

subject 5: claims 1 to 22 (all partially), 32, 33, 50-51 (both partially), 61, 62, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 6 or 6A (as far as not comprised in subjects 1-4)

subject 6: claims 1 to 22 (all partially), 34, 35, 50-51 (both partially), 63, 64, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 7 or 7A (as far as not comprised in subjects 1-5)

subject 7: claims 1 to 22 (all partially), 36, 37, 50-51 (both partially), 65, 66, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 8 or 8A (as far as not comprised in subjects 1-6)

subject 8: claims 1 to 22 (all partially), 38, 39, 50-51 (both partially), 67, 68, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 9 or 9A (as far as not comprised in subjects 1-7)

subject 9: claims 1 to 22 (all partially), 40, 41, 50-51 (both partially), 69, 70, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 10 or 10A (as far as not comprised in subjects 1-8)

subject 10: claims 1 to 22 (all partially), 42, 43, 50-51 (both partially), 71, 72, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 11 or 11A (as far as not comprised in subjects 1-9)

subject 11: claims 1 to 22 (all partially), 44, 45, 50-51 (both partially), 73, 74, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 12 or 12A (as far as not comprised in subjects 1-10)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

subject 12: claims 1 to 22 (all partially), 46, 47, 50-51 (both partially), 75, 76, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 13 or 13A (as far as not comprised in subjects 1-11)

subject 13: claims 1 to 22 (all partially), 48, 49, 50-51 (both partially), 77, 78, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 14 or 14A (as far as not comprised in subjects 1-12)

Information on patent family members

Inter onal Application No PCT/US 96/15435

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9610579 A	11-04-96	AU 3825995 A	26-04-96
WO 9402586 A	03-02-94	AU 4714493 A	14-02-94
LV 10915 B	20-04-96	NONE	
DE 3108067 A	16-09-82	EP 0059400 A JP 1594102 C JP 2019825 B JP 57158751 A	08-09-82 14-12-90 07-05-90 30-09-82

Form PCT/ISA/218 (patent family sonex) (July 1992)